Portal de Periódicos da CAPES

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study

2015; Wiley; Volume: 170; Issue: 1 Linguagem: Inglês

10.1111/bjh.13388

1365-2141

Terzah M. Horton, Richard A. Drachtman, Lu Chen, Peter D. Cole, Kathleen M. McCarten, Stephan D. Voss, R. Paul Guillerman, Allen Buxton, Scott C. Howard, Shirley Hogan, Andrea M. Sheehan, Dolores López‐Terrada, Matthew D. Mrazek, Neeraj Agrawal, Meng‐Fen Wu, Hao Liu, Pedro A. de Alarcón, Tanya M. Trippet, Cindy L. Schwartz,

Childhood Cancer Survivors' Quality of Life

Summary A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine ( IV ) in paediatric Hodgkin lymphoma ( HL ). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB . The primary endpoint was anatomic complete response ( CR ) after two cycles. Secondary endpoints included overall response ( OR : CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval ( CI ): 59–83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61–95%; p = 0·32). Although not statistically different, results suggest IVB may be a promising combination.